• October 5, 2020

    Patients with rheumatic disease are less likely to suffer from coronavirus, especially those taking hydroxychloroquine. That is why their therapy should not be interrupted during the pandemic, says rheumatologist Prof. Rasho Rashkov and clarifies that he and his colleagues have many years of experience in the treatment with hydroxychloroquine, as well as treatment of some […]

  • October 3, 2020

    Tchaikapharma High Quality Medicines Inc. remains the most expensive Bulgarian company on the Bulgarian Stock Exchange. After the market capitalization of the pharmaceutical company exceeded BGN 1 billion at the end of June, in July, August and September it added more value to its stock market valuation. The full article is available here in Bulgarian.

  • July 13, 2020

    There is a company on the Bulgarian Stock Exchange with a value of over a billion leva, according to data in the bulletin of the stock exchange operator for the second quarter. This is Tchaikapharma High Quality Medicines. By the end of June, the stock exchange players estimated the pharmaceutical company at BGN 1,027,500,000.   […]

  • July 7, 2020

    Briefing at the Ministry of health

  • June 30, 2020

    Global COVID-19 prevention trial of hydroxychloroquine to resume   LONDON (Reuters) – A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.   The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known […]

  • June 19, 2020

    MoriVid (hydroxychloroquine sulfate) 200 mg, 30 tablets, expected by thousands of Bulgarian patients, is now available in the pharmacies countrywide. The distributor of the medicinal product is Commercial League – Global Pharma Center.

  • June 16, 2020

    Prof. Toni Vekov – Director of the scientific board of Tchaikapharma, prof. Rasho Rashkov – Chairman of the Bulgarian Rheumatology Society and Boryana Boteva – Chairman of the Rheumatology Patients Organisation took part in the broadcasting “Ask BNT” related to the matters of efficiency and safety of the treatment with Hydroxychloroquine (HCQ) for rheumatology-related diseases […]

  • June 4, 2020

    (updated on 5 June, 14:30 ) In response to numerous inquiries from doctors, journalists and especially from patients suffering from autoimmune diseases, we confirm inform that Tchaikapharma High Quality Medicines Inc. has developed, produced and registered for use in Bulgaria hydroxychloroquine sulfate in one galenic form. The regulatory approval is highly anticipated and very welcomed. […]

  • April 30, 2020

    Tchaikapharma High Quality Medicines AD (BSE: 7TH) intends to build a third manufacturing plant in the village of Kazichene near Sofia. This became clear from documents published in the Commercial Register in connection with the forthcoming general meeting of shareholders, scheduled for June 22, 2020.   The investment is scheduled to be completed by the […]

  • April 13, 2020

    President Trump takes hydroxychloroquine to prevent coronavirus infection even though it’s an unproven treatment   Professor Toni Vekov in an interview with NOVA: Tchaikapharma R&D Team worked around the clock to develop our own dossier   Within the next ten days, Tchaikapharma will produce about 5,000 packs of MoriVir (hydroxychloroquine), and in another week, at […]

  • April 8, 2020

    Within a couple of days, Tchaikapharma is about to produce the first 5,000 MoriVir (hydroxychloroquin) packs for the front-line hospitals in the battle against COVID-19, and in May, another 20,000 GraVir (chloroquine) packs for further hospital treatment. “From May onwards, we expect a regular production, but it all depends on access to substances, which is […]

  • March 5, 2020

    Tchaikapharma High Quality Medicines received a thank-you letter from Prof. Diana Ivanova, Ph.D., Dean of the Pharmacy Faculty at the Varna Medical University in connection with the “empathy and friendly support”, which the company traditionally attests to graduates in Pharmacy. 54 young pharmacists graduated at this year’s graduation ceremony 2019. The original letter is available […]

  • January 7, 2020

    In 2019 Tchaikapharma (BSE:7TH) affirmed its leadership through successful development of scientific projects based on the advanced research on the development and integration of innovative combo medicines, some of which never used before in the global medical practice. Series of laboratory research and clinical studies are conducted in collaboration with European and American companies, namely […]

  • December 5, 2019

    The newest addition to Tchaikapharma High Quality Medicines Inc. prescription drugs (Rx) product list are the following:   – Zornichka (chlorthalidone) – for the treatment of arterial hypertension, essential or renovascular, or isolated systolic hypertension;   – PlaquEx Combi (clopidogrel/acetylsalicylic acid) – for the secondary prevention of acute cardiovascular events;   – Methylprednisolone -Tchaikapharma (methylprednisolone) […]

  • November 14, 2019

    Numerous spectators attended the traditional restoration of the Battle of Slivnitsa. Many volunteers were involved in the recreation of the events of the Serbo-Bulgarian War of 1885.     This year again, Tchaikapharma’s team took part in commemoration, as they traditionally participate in the recreation of historical events.   Оn November 7, 2005, the company […]

  • October 23, 2019

    Bulgaria’s Young Talents in The Field of Synthetic Biology Expressed Their Gratitude for The Support Provided Tchaikapharma High Quality Medicines Ltd. supports Bulgaria’s Team of Synthetic Biology young specialists at their participation in the biggest bio engineering contest on the Planet – iGEM. The competition takes place in Boston, USA each year and accommodates more […]

  • Tchaikapharma High Quality Medicines ranks among the leaders in the Prescription Drugs (Rx) market for the past 12 months (as of June 2019).   The ranking “Top 10 Corporations in the market for prescription products” of the world’s leading analytics company IQVIA  takes into account sales at end-customer prices, with Tchaikapharma increasing its market share […]

  • September 18, 2018

    By the end of 2018, Tchaikapharma expects to be issued with Marketing Authorizations for three new prescription drugs, which will enrich the portfolio and the well-developed therapeutic baskets of the company with the following medications and indications:   Chlorthidon (chlorthalidone) – for the treatment of arterial hypertension, essential or renovascular, or isolated systolic hypertension.   […]

  • September 12, 2018

    Tchaikapharma completed the bioequivalence clinical trials of 4 new dual-component pharmaceutical products for the treatment of arterial hypertension and other cardiovascular diseases – with sucsess. The new drug fixed-dosage combinations with angiotensin receptor blockers and thiazide or thiazide-similar diuretics represent innovative solutions for an advanced medical care.   The researched and other already registered new […]

  • May 3, 2018

    Pizona Combi contains pioglitazone and metformin that controls blood sugar levels. It helps the body to utilize better produced by body insulin when metformin alone is insufficient. The medicinal product is subject to medical prescription. For more details, please check section Products ATC код: A10B 02

  • March 29, 2018

    The 33rd National Meeting of the Association of Medical Students in Bulgaria was held in Pleven from 16 to 18 March with the support of Tchaikapharma.   A specially designed booth will welcome the participants in the eighth scientific conference of the Bulgarian Cardiac and Vascular Association under the auspices of the Rector of the […]

  • March 14, 2018

    Tchaikapharma has won award in the category of solution providers during the Pharm Connect congress which is the most notable meeting of leading pharmaceutical and biotechnology companies for Central Eastern Europe and CIS region. The excellence award was given for the successful incorporation of the latest running and implementation system. This has been a joint […]

  • April 21, 2017

    The newest addition to Tchaikapharma High Quality Medicines Inc. product list is Ivabenor 5 mg and 7,5 mg film-coated tablets. The cardiological medicinal product contains the active substance ivabradine. Ivabenor is indicated for the treatment of patients with chronic stable angina pectoris and chronic heart failure. ATC code: C01EB 17

  • April 13, 2017

    Tchaikapharma High Quality Medicines Available for All wishes you a Happy Easter!

  • March 24, 2017

    Interview with the production manager at Tchaikapharma’s plant in Plovdiv – Vasil Pavlov.   The requirements for the production of medicinal products resulting from the GMP (good manufacturing practices) enforced around the world approximate (and in many cases exceed) the requirements for operating rooms in hospitals. Medicines are produced in a rigorously monitored environment to […]

  • March 9, 2017

    Bortezomib-Tchaikapharma 3.5 mg powder for solution for injection is Tchaikapharma High Quality Medicines’ newest medicinal product which obtained a Marketing Authorisation by the Bulgarian Drug Agency in the beginning of February 2017. The active substance contained is Bortezomib (as a mannitol boronic ester). The medicinal product is subject to medical prescription. ATC code: L01XX 32

  • February 20, 2017

    Tchaikapharma High Quality Medicines Inc. received another Marketing Authorization by the Bulgarian Drug Agency with which the company updated its list of injectable products. The new oncological drug product is called Pemetrexed-Tchaikapharma 500 mg powder for concentrate for solution for infusion and is used in the treatment of malignant pleural mesothelioma and non-small cell lung […]

  • February 9, 2017

    Bortezomib-Tchaikapharma 3.5 mg powder for solution for injection is Tchaikapharma High Quality Medicines’ newest medicinal product which obtained a Marketing Authorisation by the Bulgarian Drug Agency in the beginning of February 2017. The active substance contained is Bortezomib (as a mannitol boronic ester). The medicinal product is subject to medical prescription. ATC code: L01XX 32

  • February 2, 2017

    Lidocaine-Tchaikapharma 10 mg and 20 mg solution for injection is Tchaikapharma’s newest product which has obtained a Marketing Authorization issued by the Bulgarian Drug Agency. Therapeutic indications: For local anesthesia in surgery, dentistry, urology, cardiology, ophthalmology, otorhinolaryngology and other invasive instrumental investigations. For the treatment of ventricular arrhythmias, including after myocardial infarction and cardiac surgery […]

  • December 23, 2016
  • November 23, 2016

    The renowned business ranking “300 Business Leaders in Bulgaria” for one more year honoured Tchaikapharma High Quality Medicines Inc. as one of the most profitable and influential companies in Bulgaria. The ranking’s fifth edition prepared by analysts from ICAP Group brings together the most successful companies in the country for the past year 2015, based […]

  • November 15, 2016

    The newest product of Tchaikapharma High Quality Medicines Inc., which BDA gave a marketing authorisation for, is Cilapenem 500 mg/500 mg powder for infusion solution. Each phial contains the following active substances: 530 mg imipenem monohydrate, which is equivalent to 500 mg imipenem anhydrоus, and 532 mg cilastatin sodium, equivalent to 500 mg cilastatin. The drug […]

  • November 7, 2016

    The newest medicinal product placed on the market after having received a marketing authorization from the Bulgarian Drug Agency by the Ministry of Health is the infusion solution Linezolid-Tchaikapharma 2 mg/ml. Its active substance is linezolid, and a packaging contents 300 ml x 5 pcs. or 10 pcs. This medicinal product is used in cases […]

  • September 2, 2016

    On the Bulgarian pharmaceutical market the latest addition to constantly growing product list of Tchaikapharma High Quality Medicines Inc.  for the treatment of cardiovascular diseases is offered from today. The product Cardesart-Co x 30 tablets, an international non-proprietary name Candesartan/Hydrochlorothiazide, in concentrations of active ingredients 8 mg/12.5 mg and 16 mg/12,5 mg registered under the […]

  • July 19, 2016

    After successfully completing the third for the company Decentralised Procedure (DCP) Tchaikapharma High Quality Medicines Inc. received Marketing Authorisation for the medicinal product Tamayra 5 mg/5 mg hard capsules and Tamayra 10 mg/5 mg hard capsules, for which Bulgaria is the country of reference This is the first international procedure for Marketing Authorisation of medicinal […]

  • July 14, 2016

    Tchaikapharma High Quality Medicines Inc. was granted Marketing Authorisations for the medicinal products Ibodria 6 mg/6 ml concentrate for solution for infusion and Ibodria 3 mg/3 ml solution for injection in pre-filled syringe. The active substance contained is Ibandronic acid (as ibandronate sodium monohydrate). The medicinal product is indicated for the treatment of osteoporosis in […]

  • June 30, 2016

    The Bulgarian Pharmaceutical Union awarded Tchaikapharma High Quality Medicines Inc. for cardiological medicinal product Amariton in the category “Medicinal Product Subject to Medicinal Prescription – made in Bulgaria” for 2016. The Awards ceremony took place at the Tenth anniversary edition of the Bulgarian Pharmaceutical Days, held from the 24th to 26th of June 2016 at […]

  • June 27, 2016

    Tchaikapharma High Quality Medicines Inc. was granted Marketing Authorisations for the medicinal products Atorva 40 mg and 80 mg film-coated tablets. Each tablet contains the active substance atorvastatin as atorvastatin calcium. Atorva is indicated: – as an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adults, adolescents and children […]

  • May 13, 2016

    On 10/05/2016, the BDA successfully completed within the specified period the first decentralised procedure (DCP) for marketing authorisation of medicinal products for which Bulgaria is the Reference Member State (RMS). A team of experts from the BDA assessed the documentation, in connection with the Marketing Authorisation of medicinal products Tamayra 5 mg/5 mg hard capsules […]

  • April 7, 2016

    Dear Colleagues,   Happy Holidays!   Your everyday efforts to improve people’s health and save people’s lives are and have always been worthy of respect! All impediments we face with combined efforts every day to ensure that every Bulgarian has the right of access to the most up-to-date treatment and quality life make us not […]

  • January 11, 2016

    This year again, employees of Commercial League assumed the role of Santa Claus and delighted the kids from Konstantsa Lyapcheva orphanage in the town of Dolna Banya. More than 20 children were asked to send letters with their Christmas wishes, and the team of Commercial League tried to make them true. Besides the dream gift, […]

  • November 6, 2015

    The National Health Service in the UK discontinues the coverage of 25 cancer drugs Twenty five drugs that each year give a last chance to patients with cancer – including breast, prostate and colon cancer will not be funded by the National Health Service in the UK (NHS), which plans to optimize the costs for […]

  • October 20, 2015

    Tchaikapharma High Quality Medicines Inc. was distinguished among the most profitable and influential companies in Bulgaria for the 2014 business rating “300 Business leaders in Bulgaria”. In this year’s forth edition the business analysts from the ICAP Group rated the most successful companies in the country accordingto the Earnings Before Interest, Taxes, Depreciation, and Amortization […]

  • October 6, 2015

    The participants in the National Round Table on Reforms and Healthcare without Restrictions insist that the government restores the principle “the funding follows the patient” “We do not accept and will not accept in the future the activities of the medical institutions to limit and thereby to put bounds on the rights of patients to […]

  • The specialized hospitals of the Bulgarian Cardiac Institute in Varna, Veliko Tarnovo, Shumen and Yambol mark the World Heart Day with an appeal for prevention and free consultations Every year on the 29th of September  the world celebrates the International Heart Day. In connection with this the experts reminded us that according to the “black […]

  • October 2, 2015

    For the first time clinical trials will be conducted to check if a drug prolonged life, said magazine  Sciences et Avenir. The medicine in question is metformin, which is often administered to patients affected by diabetes type 2. In 2008, the study of Russian scientists showed that it prolonged the lives of mice, probably by […]

  • According to Minister Moskov, when one has a facility in the big city where people have assets, one has to take responsibility for the system as well. According to the guild, the solution is to permit subsidiaries Administratively forcible is the method imposed by the state that out of the 4 pharmacies, which an owner […]

  • Doctors specializing in Medicine will have a right to a contract with the NHIF was decided by the MPs yesterday, when they accepted the amendments to the Law on Medical Institutions. This way they made the promise of the Health Minister Petar Moskov, which he made to the doctors in the campaign “Young Medic”, become […]

  • The Health Insurance Fund will finance hospitals only according to the needs of the population The Health Insurance Fund will not finance all newfound hospitals and will base its decisions on the National Health Card, which will have an obligatory nature. It will list the needs of the regional population. This was the bottom-line decision […]

  • September 1, 2015

    For the first time the Republic of Bulgaria, as a Member State of the EU, will be the reference country in the decentralized procedure (DCP) for Marketing Authorisation for a medicinal products with applicant Tchaikapharma High Quality Medicines Inc., Bulgaria. The concerned parties in the procedure are Austria, Greece, Portugal, Romania, Slovakia and the Czech […]